-
1
-
-
0033770342
-
5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development
-
Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299-313.
-
(2000)
Invest New Drugs
, vol.18
, pp. 299-313
-
-
Grem, J.L.1
-
2
-
-
0031788356
-
Infusional 5-FU: Historical evolution, rationale, end clinical experience
-
Lokich J. Infusional 5-FU: Historical evolution, rationale, end clinical experience. Oncology. 1998;12:19-22.
-
(1998)
Oncology
, vol.12
, pp. 19-22
-
-
Lokich, J.1
-
3
-
-
0024164649
-
Fluorouracil: Biochemistry and pharmacology
-
Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1653-1664
-
-
Pinedo, H.M.1
Peters, G.F.J.2
-
4
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its main metabolites in plasma, urine and bile
-
Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its main metabolites in plasma, urine and bile. Cancer Res. 1987;47:2203-2206.
-
(1987)
Cancer Res
, vol.47
, pp. 2203-2206
-
-
Heggie, G.D.1
Sommadossi, J.P.2
Cross, D.S.3
-
5
-
-
0032978473
-
Can pharmacokinetic monitoring improve clinical use of fluorouracil
-
Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil. Clin Pharmacokinet. 1999;36:391-398.
-
(1999)
Clin Pharmacokinet
, vol.36
, pp. 391-398
-
-
Young, A.M.1
Daryanani, S.2
Kerr, D.J.3
-
6
-
-
0033028272
-
Therapeutic drug monitoring of antimetabolic cytotoxic drugs
-
Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol. 1999;47:131-143.
-
(1999)
Br J Clin Pharmacol
, vol.47
, pp. 131-143
-
-
Lennard, L.1
-
7
-
-
0033870677
-
Comparative pharmacokinetic analysis of 5-Fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients
-
Bocci G, Danesi R, Di Paolo A, et al. Comparative pharmacokinetic analysis of 5-Fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res. 2000;6:3032-3037.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3032-3037
-
-
Bocci, G.1
Danesi, R.2
Di Paolo, A.3
-
8
-
-
0034488052
-
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
-
Van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4705-4712
-
-
Van Kuilenburg, A.B.1
Haasjes, J.2
Richel, D.J.3
-
9
-
-
0034050905
-
Known variant DPYD alleles do not explain DPD deficiency in cancer patients
-
Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217-223.
-
(2000)
Pharmacogenetics
, vol.10
, pp. 217-223
-
-
Collie-Duguid, E.S.1
Etienne, M.C.2
Milano, G.3
-
10
-
-
0029830640
-
Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: Theory and limits
-
Milano G, Etienne MC. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit. 1996;18:335-340.
-
(1996)
Ther Drug Monit
, vol.18
, pp. 335-340
-
-
Milano, G.1
Etienne, M.C.2
-
11
-
-
0037041639
-
Recuced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
-
Maring JG, van Kuilenburg AB, Haasjes J, et al. Recuced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer. 2002;86:1028-1033.
-
(2002)
Br J Cancer
, vol.86
, pp. 1028-1033
-
-
Maring, J.G.1
Van Kuilenburg, A.B.2
Haasjes, J.3
-
12
-
-
0026753035
-
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
-
Fleming A, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992;52:2899-2902.
-
(1992)
Cancer Res
, vol.52
, pp. 2899-2902
-
-
Fleming, A.1
Milano, G.2
Thyss, A.3
-
13
-
-
0034782963
-
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
-
Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12:1301-1306.
-
(2001)
Ann Oncol
, vol.12
, pp. 1301-1306
-
-
Di Paolo, A.1
Danesi, R.2
Falcone, A.3
-
14
-
-
0036785124
-
Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients
-
Di Paolo A, Ibrahim T, Danesi R, et al. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit. 2002;24:588-593.
-
(2002)
Ther Drug Monit
, vol.24
, pp. 588-593
-
-
Di Paolo, A.1
Ibrahim, T.2
Danesi, R.3
-
15
-
-
0024512054
-
5-FU therapeutic monitoring with dose adjustment leads to an inproved therapeutic index in head and neck cancer
-
Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an inproved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287-290.
-
(1989)
Br J Cancer
, vol.59
, pp. 287-290
-
-
Santini, J.1
Milano, G.2
Thyss, A.3
-
16
-
-
0028357629
-
Relationship between fluorouracil systemic exposure and tumor response and patient survival
-
Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12:1291-1295.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1291-1295
-
-
Milano, G.1
Etienne, M.C.2
Renee, N.3
-
17
-
-
0031106817
-
Simultaneous determination of DHFU and 5-fluorouracil in plasma by high-performance liquid chromatography
-
Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of DHFU and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem. 1997;246:79-85.
-
(1997)
Anal Biochem
, vol.246
, pp. 79-85
-
-
Ackland, S.P.1
Garg, M.B.2
Dunstan, R.H.3
-
18
-
-
0035950466
-
High-performance liquid chromatography assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: Application to measurment of dihydropyrimidine dehydrogenase activity
-
Déporte-Féty A, Picot M, Amiand M, et al. High-performance liquid chromatography assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurment of dihydropyrimidine dehydrogenase activity. J Chromatogr B. 2001;762:203-209.
-
(2001)
J Chromatogr B
, vol.762
, pp. 203-209
-
-
Déporte-Féty, A.1
Picot, M.2
Amiand, M.3
-
19
-
-
0028334435
-
Determination of the concentrations of 5-fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography
-
Del Nozal MJ, Bernal JL, Pampliega A, et al. Determination of the concentrations of 5-fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography. J Chromatogr B. 1994;656:397-405.
-
(1994)
J Chromatogr B
, vol.656
, pp. 397-405
-
-
Del Nozal, M.J.1
Bernal, J.L.2
Pampliega, A.3
-
20
-
-
0021022886
-
A gas chromatographic assay for the determination of 5,6- dihydrofluorouracil and 5-fluorouracil in human plasma
-
De Bruijn EA, Driessen O, van den Bosch N, et al. A gas chromatographic assay for the determination of 5,6-dihydrofluorouracil and 5-fluorouracil in human plasma. J Chromatagr B. 1983;278:283-289.
-
(1983)
J Chromatagr B
, vol.278
, pp. 283-289
-
-
De Bruijn, E.A.1
Driessen, O.2
Van Den Bosch, N.3
-
21
-
-
0036808430
-
Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients
-
Casale F, Canaparo R, Muntoni E, et al. Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients. Biomed Chromatogr. 2002;16:446-452.
-
(2002)
Biomed Chromatogr
, vol.16
, pp. 446-452
-
-
Casale, F.1
Canaparo, R.2
Muntoni, E.3
-
22
-
-
84988175795
-
Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies
-
Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;81:309-312.
-
(1992)
J Pharm Sci
, vol.81
, pp. 309-312
-
-
Shah, V.P.1
Midha, K.K.2
Dighe, S.3
-
23
-
-
0032754717
-
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography
-
Loos WJ, de Bruijn P, van Zuylen L, et al. Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;735:293-297.
-
(1999)
J Chromatogr B Biomed Sci Appl
, vol.735
, pp. 293-297
-
-
Loos, W.J.1
De Bruijn, P.2
Van Zuylen, L.3
-
24
-
-
0023473360
-
The stability of 5,6-dihydrofluorouracil in plasma and the consequences for its analysis
-
Van den Bosch N, Driessen O, Van der Velde EA, et al. The stability of 5,6-dihydrofluorouracil in plasma and the consequences for its analysis. Ther Drug Monit. 1987;9:443-447.
-
(1987)
Ther Drug Monit
, vol.9
, pp. 443-447
-
-
Van Den Bosch, N.1
Driessen, O.2
Van Der Velde, E.A.3
-
25
-
-
0037328454
-
Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics
-
Maring JG, Piersma H, Van Dalen A, et al. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemother Pharmacol. 2003;51:167-173.
-
(2003)
Cancer Chemother Pharmacol
, vol.51
, pp. 167-173
-
-
Maring, J.G.1
Piersma, H.2
Van Dalen, A.3
|